Veranex Presents Study Results at the National Kidney Foundation Spring Clinical Meeting
Dr. Manasi Datar and colleagues used conjoint analysis to estimate preferences regarding kidney disease testing from 401 PCPs via a web survey....
Study by Veranex and Thermo Fisher Highlights Payer Budget Impact of Novel Test for Kidney Transplant Rejection
admin.veranex : Mar 24, 2025 10:23:06 PM
By developing a U.S. payer budget impact model and associated manuscript for Thermo Fisher’s Molecular Microscope® MMDx®-Kidney (a microarray with machine learning for kidney biopsy interpretation), Veranex supported Thermo Fisher’s efforts to communicate the test’s value for evaluating kidney transplant rejection and to facilitate commercial payer acceptance of the test.
Study by Veranex and Proteomics International Demonstrates Clinical Utility of Prognostic Test for Type 2 Diabetes Patients
admin.veranex : Mar 24, 2025 10:23:07 PM
By conducting a clinical utility study for Proteomics International’s PromarkerD (a blood-based test that predicts the risk of kidney...
Demonstrating Clinical Utility Using a Validated Methodology From the Market Research Toolkit
admin.veranex : Mar 24, 2025 10:23:08 PM
Veranex Director Lauren Fusfeld uses a case study to show how conjoint analysis can demonstrate to payers and health care providers the clinical...